TheStreet.com Network: MainStreet.com | StockPickr.com | BankingMyWay.com | Geezeo Budget Planner | RealMoney | Nails on the Numbers (NEW)
TheStreet.com
 ACCESS REALMONEY
 ADVISORS NOW!
Subscribe to Expert Advisors
Free Newsletters
  • Headlines & Perspectives
  • Business News
  • TheStreet Picks
  • Video
  • Investing A-to-Z
  • Life & Money
  • Portfolio & Tools
  • $ Services
  • Action Alerts PLUS - $50 off
  • Portfolio
  • Calculators
  • Stockpickr
  • Street Answers
  • Mad Money Performance
  • Stock Screener
  • Mutual Fund Screener
  • ETF Screener
  • Banks & Thrifts Screener
  • Insurers & HMOs Screener
  • Glossary
  • Horo$copes
  • Cramer's Action Alerts PLUS
  • Breakout Stocks
  • Daily Swing Trade
  • Dividend Stock Advisor
  • ETF Shark Alerts
  • InsiderInsights(NEW)
  • Nails On The Numbers(NEW)
  • Options Alerts
  • Ratings Services
  • RealMoney
  • RealMoney Silver
  • Stocks Under $10
  • Telecom Connection
  • Top Stocks
  • Value Investor
  • Cramer's Action Alerts PLUS
  • Breakout Stocks
  • Daily Swing Trade
  • Dividend Stock Advisor
  • ETF Shark Alerts
  • InsiderInsights(NEW)
  • Nails On The Numbers(NEW)
  • Options Alerts
  • Ratings Services
  • RealMoney
  • RealMoney Silver
  • Stocks Under $10
  • Telecom Connection
  • Top Stocks
  • Value Investor
  • Action Alerts PLUS - $50 off
  • Portfolio
  • Calculators
  • Stockpickr
  • Stockpickr Answers
  • Geezeo Confessions
  • Mad Money Performance
  • Stock Screener
  • Mutual Fund Screener
  • ETF Screener
  • Banks & Thrifts Screener
  • Insurers & HMOs Screener
  • Glossary
  • Horo$copes

Biotech

« Back
Page 2 of 121
Next »
Article

Icahn Loses Battle for Biogen Board Seats

By Elizabeth Trotta

The biotech company's slate of nominees wins the vote.

Related Topics: Drugs | Health Care | Biotech

12:08PM 06/19/08

Article

Biotech Review: Elan's Alzheimer's Drug

By Adam Feuerstein

The promising data sent shares soaring Tuesday; here's what investors need to know now.

Related Topics: Biotech | Drugs | Health Care

07:09AM 06/18/08

Video

The Real Story Wrap: June 17

By Frank Curzio

Stocks in the U.S. struggled for much of the session Tuesday and closed lower as investors shrugged off decent monthly inflation data and an earnings beat from Goldman Sachs GS.

Related Topics: Markets | Energy | Technology | Retail | Telecom | Biotech | Software | Media | Consumer Goods

04:37PM 06/17/08

Article

A Quiet Medicines Co. Raises Questions

By Adam Feuerstein

The CEO last week disclosed a regulatory hiccup in its application for Cleviprex, months after the FDA first informed the company of a delay.

Related Topics: Drugs | Biotech | Health Care

07:46AM 06/17/08

Article

Elan Reports Mixed Alzheimer Results

By Adam Feuerstein

The Elan and Wyeth drug was at least partially effective in a subgroup of patients lacking a higher genetic risk for developing Alzheimer's.

Related Topics: Health Care | Biotech | Drugs

06:49AM 06/17/08

Article

Acadia Shares Sink on Failed Study

By Elizabeth Trotta

A midstage trial for schizophrenia drug ACP-104 didn't meet its primary or secondary endpoints.

Related Topics: Drugs | Health Care | Biotech

11:02AM 06/16/08

Article

Biotech Watch: Elan's Alzheimer's Drug Data

By Adam Feuerstein

The potential market for bapineuzumab is massive. Here's how to sort the trial data when released.

Related Topics: Health Care | Biotech | Drugs

12:41PM 06/13/08

Article

Biotech-Stock Mailbag: Sangamo

By Adam Feuerstein

Weighing chances for Sangamo's lead pipeline drug, and more.

Related Topics: Biotech | Fundamental Analysis

06:59AM 06/13/08

Video

The Real Story Wrap: June 12

By Frank Curzio

Stocks in New York closed in the green Thursday, though the major averages fell off their session highs as oil rebounded from an early decline and Yahoo! YHOO shares sank in the afternoon.

Related Topics: Markets | Telecom | Financial Services | Media | Retail | Biotech | Banks | Technology

05:00PM 06/12/08

Article

Invitrogen, Applied Biosystems Ink Merger

By Elizabeth Trotta

The biotech will pay $38 a share, or about $6.7 billion, for the instruments company in a combination of cash and stock.

Related Topics: Drugs | M&A | Health Care | Biotech

09:37AM 06/12/08

Article

Genentech Settles Patent Dispute With MedImmune

By Elizabeth Trotta

Genentech said it is not updating its royalty revenue guidance.

Related Topics: Drugs | Biotech | Health Care

06:08PM 06/11/08

Article

Court Docs: Icahn Mulled $76-$82/Share for Biogen

By Elizabeth Trotta

Bloomberg reports the activist investor revealed he might have been willing to pay up to $15 billion last fall.

Related Topics: Health Care | Drugs | Biotech

12:07PM 06/11/08

Article

Biotech Notebook: Vertex, Medicines Co.

By Adam Feuerstein

Uncertain regulation hangs on Vertex's telaprevir, The Medicines Co. remains mum on Cleviprex and a summer biotech-stock watch list.

Related Topics: Health Care | Biotech | Drugs

10:09AM 06/10/08

Article

Vertex Unveils More Upbeat Hep C Drug Data

By Adam Feuerstein

Its telaprevir reduced levels of the virus down to undetectable levels in 52% of difficult-to-treat patients.

Related Topics: Drugs | Biotech | Health Care

10:28AM 06/09/08

Article

How to Hedge: Indevus Pharmaceuticals

By Jonas Elmerraji

What if you could get an insurance policy for your portfolio? With hedging, you can. Here's how.

Related Topics: Biotech | ETFs | Strategy | Personal Finance | Options/Futures Basics | Short-Selling

01:33PM 06/06/08

« Back
Page 2 of 121
Next »
Your Recent Quotes: Quote Up0 | Quote Down0
Dow S&P 500 NASDAQ
Oil*
Gold
10 Yr
0.00%
%
%
%
Data delayed 20 min
Sign up for our FREE newsletters now.

Keep on top of the market and the critical information you need to make more profitable investing decisions.

  • Cramer's Daily Booyah!
  • Before the Bell
Submit

Privacy Policy

See All Free Newsletters

Financial Tools

Financial Glossary

Enhance your investing education as you read articles on TheStreet.com. Look for the symbol throughout our site to look up items. Browse Glossary

Check a Rating

How does your portfolio rate? Enter a ticker below or go straight to our screeners: Stocks| ETFs| Funds

Sponsored by:

Premium Services

Action Alerts PLUS | Stocks Under $10 | RealMoney | Options Alerts | Breakout Stocks | Top Stocks | VIEW ALL

Get Cramer's portfolio stock picks at Action Alerts PLUS — take $50 off
Find Dykstra's DITM calls only here — save $100 on Nails on the Numbers
Investing pros give you their take on the market — RealMoney now $100 off
Profit from legal insider trading — start with $50 off Insider Insights
View Directory
Jim Cramer's Action Alerts PLUS RealMoney RealMoney Silver Options Alerts Stocks Under $10 Top Stocks Nails on the Numbers(NEW)

Resources
  • About Us
  • Advertise
  • Corrections
  • Customer Service
  • Employment
  • Investor Relations
  • Log In
  • Privacy Policy
  • Readers' Feedback
  • Subscribe
  • Terms of Use
TheStreet Premium Services
Cramer's Action Alerts PLUS:  Inside his portfolio
More Info | Free Trial | Subscribe | Login
Breakout Stocks:  Get in before they're hot
More Info | Free Trial | Subscribe | Login
Daily Swing Trade:  Play on market moves
More Info | Free Trial | Subscribe | Login
Dividend Stock Advisor:  Stable income investing
More Info | Free Trial | Subscribe | Login
ETF Shark Alerts:  Winning opportunities
More Info | Free Trial | Subscribe | Login
InsiderInsights:  Picks based on insider trading data
More Info | Free Trial | Subscribe | Login
Nails on the Numbers:  Dykstra's DITM calls
More Info | Free Trial | Subscribe | Login
Options Alerts:  Let volatility work for you
More Info | Free Trial | Subscribe | Login
RealMoney:  Pros' ideas & strategies
More Info | Free Trial | Subscribe | Login
RealMoney Silver:  5 key investor services
More Info | Free Trial | Subscribe | Login
Stocks Under $10:  Low price/high potential
More Info | Free Trial | Subscribe | Login
Telecom Connection:  Essential investing info
More Info | Free Trial | Subscribe | Login
Top Stocks:  Masterful market charts
More Info | Free Trial | Subscribe | Login
Value Investor:  Top undervalued stocks
More Info | Free Trial | Subscribe | Login
Ratings Services:  Data you can bank on
More Info | Unlimited Reports
Free Newsletters
See All Free Newsletters

After the Bell

Before the Bell

Booyah! Newsletter

ETF Weekly

Midday Bell

TSC Top Ten Stories Newsletter

University Newsletter

Winners & Losers

Privacy Policy
Podcasts
RSS Feed Daily RSS Updates

TheStreet Mobile Edition

Take Our Tour